The Europe Hearing Loss Disease Treatment Market would witness market growth of 4.0% CAGR during the forecast period (2022-2028).
The hearing devices sector could be divided into ITE (in the ear), BTE (behind the ear), CIC (completely in the canal), RIC (receiver in the canal), & others (invisible in the canal). Among the various kinds of hearing aids, the BTE (behind-the-ear) is a hugely growing sector with the highest demand.
Therefore, BTE (behind-the-ear) devices are anticipated to drive the hearing loss disease treatment market in the upcoming years. If the hearing aids are not helpful, a cochlear implant is employed to repair hearing because of inner ear injury. Cochlear implants are distinctive electronic devices and are accessible to employ in adults & children hurting from severe hearing impairment or deafness.
During the last few years, various cochlear implants have been authorized by health organizations, including FDA. One can also opt surgery option in case of severe damage to outer or middle ear. In the surgical process, ear reconstruction through stapedotomy, tympanoplasty, ossicular chain reconstruction, aural atresia repair, and others are conducted to restore & improve hearing.
According to the government of the UK, one to two infants out of a thousand are born with lifelong hearing loss in both or one of the ears. Mostly these infants are born in such families that have no past of hearing loss. Further, the United Kingdom's life science industry contributes remarkably to the nation's economy. It hires 256,100 people and has a total income of £80.7 billion. Furthermore, with more than 2,000 businesses, and over 80% of them belong to SMEs, the UK's medical technology segment hires 100,000 people, thus making it the second-largest manufacturer in Europe after Germany. This allows the accessibility of trained healthcare suppliers for improved healthcare services. The increasing cases of hearing loss, together with the robust healthcare infrastructure, are expected to increase the market growth.
The Germany market dominated the Europe Hearing Loss Disease Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,287.7 Million by 2028.The UK market is experiencing a CAGR of 3.2% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 4.8% during (2022 - 2028).
Based on Disease Type, the market is segmented into Sensorineural, Conductive and Mixed. Based on Product, the market is segmented into Devices and Drugs. Based on End-user, the market is segmented into Otology Clinics, Hospitals and Ambulatory Clinics. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Astellas Pharma, Inc, WS Audiology A/S, Otonomy, Inc, Sensorion, Frequency Therapeutics, Inc, Acousia Therapeutics GmbH, Pipeline Therapeutics, Inc, Audina Hearing Instruments, Inc, and Audifon GmbH & CO. KG.
The hearing devices sector could be divided into ITE (in the ear), BTE (behind the ear), CIC (completely in the canal), RIC (receiver in the canal), & others (invisible in the canal). Among the various kinds of hearing aids, the BTE (behind-the-ear) is a hugely growing sector with the highest demand.
Therefore, BTE (behind-the-ear) devices are anticipated to drive the hearing loss disease treatment market in the upcoming years. If the hearing aids are not helpful, a cochlear implant is employed to repair hearing because of inner ear injury. Cochlear implants are distinctive electronic devices and are accessible to employ in adults & children hurting from severe hearing impairment or deafness.
During the last few years, various cochlear implants have been authorized by health organizations, including FDA. One can also opt surgery option in case of severe damage to outer or middle ear. In the surgical process, ear reconstruction through stapedotomy, tympanoplasty, ossicular chain reconstruction, aural atresia repair, and others are conducted to restore & improve hearing.
According to the government of the UK, one to two infants out of a thousand are born with lifelong hearing loss in both or one of the ears. Mostly these infants are born in such families that have no past of hearing loss. Further, the United Kingdom's life science industry contributes remarkably to the nation's economy. It hires 256,100 people and has a total income of £80.7 billion. Furthermore, with more than 2,000 businesses, and over 80% of them belong to SMEs, the UK's medical technology segment hires 100,000 people, thus making it the second-largest manufacturer in Europe after Germany. This allows the accessibility of trained healthcare suppliers for improved healthcare services. The increasing cases of hearing loss, together with the robust healthcare infrastructure, are expected to increase the market growth.
The Germany market dominated the Europe Hearing Loss Disease Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,287.7 Million by 2028.The UK market is experiencing a CAGR of 3.2% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 4.8% during (2022 - 2028).
Based on Disease Type, the market is segmented into Sensorineural, Conductive and Mixed. Based on Product, the market is segmented into Devices and Drugs. Based on End-user, the market is segmented into Otology Clinics, Hospitals and Ambulatory Clinics. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Astellas Pharma, Inc, WS Audiology A/S, Otonomy, Inc, Sensorion, Frequency Therapeutics, Inc, Acousia Therapeutics GmbH, Pipeline Therapeutics, Inc, Audina Hearing Instruments, Inc, and Audifon GmbH & CO. KG.
Scope of the Study
Market Segments Covered in the Report:
By Disease Type
- Sensorineural
- Conductive
- Mixed
By Product
- Devices
- Drugs
By End-user
- Otology Clinics
- Hospitals
- Ambulatory Clinics
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Astellas Pharma, Inc
- WS Audiology A/S
- Otonomy, Inc
- Sensorion
- Frequency Therapeutics, Inc
- Acousia Therapeutics GmbH
- Pipeline Therapeutics, Inc
- Audina Hearing Instruments, Inc
- Audifon GmbH & CO. KG
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Hearing Loss Disease Treatment Market, by Disease Type
1.4.2 Europe Hearing Loss Disease Treatment Market, by Product
1.4.3 Europe Hearing Loss Disease Treatment Market, by End-user
1.4.4 Europe Hearing Loss Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Hearing Loss Disease Treatment Market
Chapter 4. Europe Hearing Loss Disease Treatment Market by Disease Type
4.1 Europe Sensorineural Market by Country
4.2 Europe Conductive Market by Country
4.3 Europe Mixed Market by Country
Chapter 5. Europe Hearing Loss Disease Treatment Market by Product
5.1 Europe Devices Market by Country
5.2 Europe Drugs Market by Country
Chapter 6. Europe Hearing Loss Disease Treatment Market by End-user
6.1 Europe Otology Clinics Market by Country
6.2 Europe Hospitals Market by Country
6.3 Europe Ambulatory Clinics Market by Country
Chapter 7. Europe Hearing Loss Disease Treatment Market by Country
7.1 Germany Hearing Loss Disease Treatment Market
7.1.1 Germany Hearing Loss Disease Treatment Market by Disease Type
7.1.2 Germany Hearing Loss Disease Treatment Market by Product
7.1.3 Germany Hearing Loss Disease Treatment Market by End-user
7.2 UK Hearing Loss Disease Treatment Market
7.2.1 UK Hearing Loss Disease Treatment Market by Disease Type
7.2.2 UK Hearing Loss Disease Treatment Market by Product
7.2.3 UK Hearing Loss Disease Treatment Market by End-user
7.3 France Hearing Loss Disease Treatment Market
7.3.1 France Hearing Loss Disease Treatment Market by Disease Type
7.3.2 France Hearing Loss Disease Treatment Market by Product
7.3.3 France Hearing Loss Disease Treatment Market by End-user
7.4 Russia Hearing Loss Disease Treatment Market
7.4.1 Russia Hearing Loss Disease Treatment Market by Disease Type
7.4.2 Russia Hearing Loss Disease Treatment Market by Product
7.4.3 Russia Hearing Loss Disease Treatment Market by End-user
7.5 Spain Hearing Loss Disease Treatment Market
7.5.1 Spain Hearing Loss Disease Treatment Market by Disease Type
7.5.2 Spain Hearing Loss Disease Treatment Market by Product
7.5.3 Spain Hearing Loss Disease Treatment Market by End-user
7.6 Italy Hearing Loss Disease Treatment Market
7.6.1 Italy Hearing Loss Disease Treatment Market by Disease Type
7.6.2 Italy Hearing Loss Disease Treatment Market by Product
7.6.3 Italy Hearing Loss Disease Treatment Market by End-user
7.7 Rest of Europe Hearing Loss Disease Treatment Market
7.7.1 Rest of Europe Hearing Loss Disease Treatment Market by Disease Type
7.7.2 Rest of Europe Hearing Loss Disease Treatment Market by Product
7.7.3 Rest of Europe Hearing Loss Disease Treatment Market by End-user
Chapter 8. Company Profiles
8.1 Novartis AG
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.2 Astellas Pharma, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 WS Audiology A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Otonomy, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.5 Sensorion
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Partnerships, Collaborations, and Agreements:
8.6 Frequency Therapeutics, Inc
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Partnerships, Collaborations, and Agreements:
8.7 Acousia Therapeutics GmbH
8.7.1 Company Overview
8.8 Pipeline Therapeutics, Inc
8.8.1 Company Overview
8.9 Audina Hearing Instruments, Inc.
8.9.1 Company Overview
8.10. Audifon GmbH & CO. KG
8.10.1 Company Overview
Companies Mentioned
- Novartis AG
- Astellas Pharma, Inc
- WS Audiology A/S
- Otonomy, Inc
- Sensorion
- Frequency Therapeutics, Inc
- Acousia Therapeutics GmbH
- Pipeline Therapeutics, Inc
- Audina Hearing Instruments, Inc
- Audifon GmbH & CO. KG
Methodology
LOADING...
